Oncoarendi Therapeutics S.a.

Molecure S.a.

Oncoarendi Therapeutics Sp. Z O.o.

Molecure Spolka Akcyjna

Krzysztof Matyszewski

Adam A Golebiowski

Jacek P Olczak

Bartlomiej Borek

Sylwia Olejniczak

Robert Koralewski

Anna Gzik

Julita Nowicka

Marzena Mazur

Wojciech J Czestkowski

Roman Blaszczyk

Marek Dziegielewski

Karol Jedrzejczak

Agnieszka Bartoszewicz

Joanna Brzezińska

Piotr Niedziejko

Paul Beckett

Adam Golebiowski

Joanna Brzezinska

Michal L Kowalski

Katarzyna Krysztofiak

Angelika Muchowicz

Jacek Olczak

Lukasz Joachimiak

Sylwia Ciastek-Iskrzycka

Gleb Andryianau

Zbigniew Zasłona

Łukasz Joachimiak

Barbara Dymek

Adam Gołębiowski

Jacek Chrzanowski

Łukasz Krzemiński

Elżbieta Pluta

Roman Błaszczyk

Rafał Kozieł

Jacek Olozak

Michał Kowaiski

Michal Czesław Piotrowicz

Paul R Beckett

The inventive compounds are small molecule therapeutics that are potent inhibitors of USP7 activity. The invention also provides pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease, disorder, or condition associated with USP7 activity.

Deubiquitinase inhibitors and methods of use thereof

Disclosed are assays for screening active compounds interfering with interaction between chitinase-like protein YKL-40 and chitin oligomers, as well as interfering with interaction between chitinase-like protein YKL-40 and heparan sulfate. Moreover, disclosed are active compounds identified by these assays as inhibitors of chitinase-like protein YKL-40, their therapeutic applications, and their use in biosensors measuring the level of chitinase-like protein YKL-40 in biological samples.

YKL-40 inhibitors and their therapeutic

Disclosed are small molecule therapeutic compounds that are potent inhibitors of arginase 1 and arginase 2 activity. Also disclosed are pharmaceutical compositions comprising the compounds, and methods for using the compounds for treating or preventing a disease or condition associated with arginase activity.

Arginase inhibitors and their therapeutic applications

Disclosed are amino triazole compounds of formula (I). These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase. Also disclosed are methods of using the compounds to treat asthma reactions caused by allergens, as well as acute and chronic inflammatory diseases, autoimmune diseases, dental diseases, neurologic diseases, metabolic diseases, liver diseases, polycystic ovary syndrome, endometriosis, and cancer. 

Substituted amino triazoles useful as chitinase inhibitors

Disclosed are amino triazole compounds substituted by a carboxylate functional group or an bioisosteric polar functional group. Compounds having the carboxylate moiety or carboxylate bioisostere inhibit acidic mammalian chitinase. Also provided are methods of using the compounds to treat asthma reactions caused by allergens.

Substituted amino triazoles useful as acidic mammalian chitinase inhibitors

Growing community of inventors

Lodz, Poland

Krzysztof Matyszewski